Phase 3 Daraxonrasib Trial Nearly Doubles Survival In Metastatic Pancreatic Cancer
Jun 04
6
On Sunday, May 31, 2026, Phase 3 data presented at ASCO showed the oral KRAS inhibitor daraxonrasib nearly doubled median survival in 500 patients with previously treated metastatic pancreatic cancer. NPR
